DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Cardiology Homepage

Pre-activating cardiac catherization labs benefits EMS STEMI patients on arrival Saves critical minutes and can bypass typical ED protocols

Apple Watch can monitor heart rhythms with FDA approval Detects atrial fibrillation and can tell if you've taken a sudden fall

Keith D. Dawkins InnovHeart elects chairman of the board

Jeffrey S. Brown Endologix appoints chief operations officer

Bioengineers create virtual 3D heart with AI Could provide a boost to the treatment of atrial fibrillation

Fractional flow reserve CT can reduce invasive heart procedures: study First clinical study on benefits of FFRCT for moderate stenosis

Philips unveils new ultrasounds for general and interventional cardiology Equipped with anatomical intelligence

Boston Scientific to buy VENITI for $160 million Price may rise pending FDA approval of Vici Venous Stent

MaxQ-AI seeks $8 million public IPO listing on Nasdaq Will help FDA regulatory processes for Accipio software products

NIH grants $1.5 million to Magnetic Insight for development of new imaging modality Uses non-radioactive, iron oxide nanoparticle tracer

MyoVista high sensitivity
electrocardiograph Testing Device

New advanced ECG tool for cardiac disease now available in Europe

by John R. Fischer , Staff Reporter
European cardiologists may soon be able to detect the presence of heart disease more effectively in patients, thanks to a new advanced ECG tool.

HeartSciences’ MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device is now available for sale and distribution in markets across the European Union, following CE approval.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Our device performs all of the functions that normal resting ECG does that you would expect in a higher performance 12-lead, resting ECG that hospitals would use, for instance,” Mark Hilz, president and CEO of HeartSciences, said. “Our device performs all those functions, plus it provides additional informatics that will provide additional information related to cardiac dysfunction.”

MyoVista hsECG uses continuous wavelet transform, an advanced form of signal processing, to transform ECG signals into energy distribution during the cardiac cycle. Traditional ECG only examines analog waveforms of signals.

The device then analyzes the signals to measure the energy of the heart during each heartbeat, especially during its resting stage, with HeartSciences asserting that the use of continuous wavelet transform increases the sensitivity of detection in the device for the presence of cardiac disease.

“Once we’ve transformed the wave form, we look at the T-form, the resting stage, which is when sub-clinical heart disease typically manifests itself,” Hilz said. “So, if you have structural disease such as valve disease or hypotrophy or cardiomyopathy, or you have coronary arterial disease, it’s typically going to be seen in the resting phase or the diastolic phase, which is when the T-wave occurs.”

A trial conducted for the presence of left ventricular diastolic dysfunction in 200 patients found that the devices showed 88% sensitivity and 87% specificity in detecting cardiac dysfunction in the diastolic phase of the cardiac cycle.

It uses the same 12-lead, at-rest testing protocol as traditional ECG, making it easier for physicians and clinical staff to quickly assimilate it for use. But the device can also act as one single test, is less costly than traditional ECG tools, may be used on asymptomatic patients, and could be used to detect cardiac disease in patients at an earlier stage.

“ECG technology has been around for a hundred plus years. For a hundred plus years, they’ve been looking at that normal cardiac monitor wave form, and we are the first ones to use signal processing to transform the waveform … we’ve transformed the waveform and found very useful data on whether heart disease is present, whether there is true dysfunction related to structural or coronary arterial disease.”

HeartSciences is currently working to obtain approval for MyoVista hsECG in Australia, Canada, Latin America, the Middle East and Asia-Pacific. It is seeking to submit the device for FDA approval in 2018.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED